N-Power Medicine, a company leading the transformation of the clinical trial process, announced the acquisition of Syapse, an innovator in precision medicine solutions for community cancer centers. N-Power’s acquisition of Syapse was completed through a stock-for-stock exchange on December 30, 2024. Innovatus Capital Partners (Syapse’s lead institutional investor) joins N-Power’s existing investors, including the Merck Global Health Innovation Fund (GHI) and a U.S.-based healthcare-focused investor, in providing ongoing funding for N-Power’s goals.
This integration of Syapse into N-Power Medicine includes Syapse’s extensive network of community-based health systems, with over 1,000 oncologists, its data and technology stack, and its dedicated team. And N-Power partners with community oncologists through its proprietary real-time Kaleido Registry and AI-enabled point-of-care platform, complemented by virtual and on-site support, to optimize research and patient care workflows.
This deal will establish the largest community-based prospective clinical research network where every patient, through N-Power’s platform, will have research-ready data and documentation as part of their routine care. And the expanded N-Power network will also help tackle the critical gaps in patient access to clinical trials in the community setting, where more than 80% of U.S. cancer patients— especially those from diverse and underrepresented populations — receive their care.
The deal will enhance the company’s current offerings to its growing pharmaceutical customers, including Merck, who are engaged in a multi-trial collaboration with N-Power. And N-Power can now offer significantly greater access to a more representative group of geographically diverse, U.S. community-based cancer patients for clinical trial enrollment. A better network scale will also enable the rapid and rigorous generation of prospective external controls, allowing for smaller and faster clinical trials.
Canaccord Genuity acted as Syapse’s exclusive financial advisor during this transaction.
KEY QUOTES:
“The integration of Syapse into N-Power underscores our commitment to dramatically accelerating drug development and improving the probability of success by seamlessly integrating clinical research into every oncologist’s practice and every cancer patient’s care. With this scale, N-Power accelerates the transformation of drug development that our pharma customers are asking for – enabling local access to clinical trials for more community oncologists and community cancer patients than ever before and by creating a unique platform for generating prospective external controls, reducing the need for randomized trials.”
– Mark Lee, M.D., Ph.D, the Co-Founder and Chief Executive Officer of N-Power Medicine
“Syapse joining N-Power represents a transformative step forward in our shared mission to revolutionize community-based patient care. By building upon Syapse’s existing offerings for its health system and pharma partners with N-Power’s AI-enabled ‘human-in-the-loop’ approach, we can significantly expand access to prospective clinical trials and life-saving innovations for patients in community settings. We are proud to join N-Power in building a future where community oncology serves as a powerful catalyst for research and improved patient outcomes.”
– Michael Mentesana, the Chief Executive Officer of Syapse
